市場調査レポート

抗菌薬

Antibacterial Drugs

発行 Global Industry Analysts, Inc. 商品コード 121122
出版日 ページ情報 英文 719 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
抗菌薬 Antibacterial Drugs
出版日: 2010年04月01日 ページ情報: 英文 719 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、世界の抗菌薬市場について調査分析し、抗菌薬の概要と種類、細菌感染の治療法、近年の製品上市と治験動向とともに、参入企業のプロファイルと地域・国別の市場などについてまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション・調査手法・製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 世界市場見通し
    • 抗菌耐性:成長阻害因子
    • 抗菌耐性コスト高
    • 特許期限満了
    • ジェネリック薬との競争激化
    • 抗菌薬市場を独占するセファロスポリン
    • 急速に拡大するマクロライドとフルオロキノロン類
    • 主な参入企業とブランド
    • 米国が世界市場をリードするも他の地域も急速に拡大
  • 抗菌薬クラス:レビュー
    • セファロスポリン
    • フルオロキノロン類
    • マクロライド
    • ペニシリン
    • その他
  • 細菌感染と治療の概要と治療法
    • 細菌感染
    • 主な細菌感染の概要
    • 細菌と闘う抗菌薬
    • 抗菌薬の分類
    • 抗菌薬のクラスとその使用
    • 抗菌治療の限界
    • ファージ治療:細菌感染の有望なアプローチ
  • 製品導入/認可/治験
  • 最近の市場活動
  • 主要企業
    • Abbott Laboratories
    • AstraZeneca PLC
    • Bayer HealthCare AG
    • Bristol-Myers Squibb Co.
    • Cubist Pharmaceuticals, Inc.
    • 第一三共
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Pfizer, Inc.
    • Wyeth Pharmaceuticals, Inc.
  • 世界市場の見通し

第3章 市場

  • 米国
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • その他
  • アジア太平洋諸国
  • その他地域

第4章 競合情勢

  • 企業プロファイル
目次
Product Code: MCP-6168

Abstract

This report analyzes the worldwide markets for Antibacterial Drugs in US$ Million by the following drug classes: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Antibacterial Drugs. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 124 companies including many key and niche players such as Abbott Laboratories, AstraZeneca PLC, Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Other Antibacterial Drugs

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Global Market Outlook
  • Antibacterial Resistance - A Key Growth Dampener
  • Antibacterial Resistance Costs High
  • Patent Expiries Commoditize Antibacterials Market
  • Patent Expiries of Major Anti-Bacterial Drugs
  • Generic Competition Intensifies
  • Cephalosporins Dominate the Anti-bacterials Market
  • Table 1: Worldwide Market for Anti-Bacterials by Major Drug Class (2010): Percentage Share Breakdown for Cephalosporins, Penicillins, Fluoroquinolones ,Macrolides, and Others (includes corresponding Graph/Chart)
  • Macrolides and Fluoroquinolones to Grow At a Faster Rate
  • Major Players and Key Brands
  • Table 2: Select Major Anti-Bacterial Drugs Worldwide (2008 & 2007): Value Sales in US$ Million for Levaquin/ Floxin, Zosyn/Tazocin, Zyvox, Augmentin, Merrem, Primaxin, Avelox/Avalox, Cravit, Zithromax/Zmax, Cipro/ Ciprobay, Rocephin (includes corresponding Graph/Chart)
  • United States Leads the Global Market, Other Regions to Exhibit Faster Growth
  • Injectables Gain Traction

2. ANTI-BACTERIAL DRUG CLASSES -

A REVIEW
  • Cephalosporins
  • Select Major Cephalosporins Worldwide
  • List of Select Cephalosporin Drugs by Generation
  • Drug Details of Select Cephalosporins
  • Omnicef (Abbott Laboratories)
  • Rocephin (Roche)
  • Maxipime (Bristol Myers Squibb/Elan)
  • Zinnat (GlaxoSmithKline)
  • Spectracef (Cornerstone BioPharma)
  • Fluoroquinolones
  • Select Major Fluoroquinolones Worldwide
  • Drug Details of Select Fluoroquinolones
  • Levaquin/Floxin/Cravit (Ortho-McNeil-Janssen/ Daiichi Sankyo)
  • Brand Names of Levofloxacin in Different Regions
  • Avelox (Bayer)
  • Ciprofloxacin (Various)
  • Macrolides
  • Drug Details of Select Macrolides
  • Biaxin (Abbott)
  • Zmax (Pfizer Inc.)
  • Penicillins
  • Select Penicillins Worldwide
  • Table 3: Sales of Leading Penicillin Drugs in US$ Million (2006-2008) (includes corresponding Graph/Chart)
  • Drug Details of Select Penicillins
  • Augmentin (GlaxoSmithKline)
  • Zosyn (Wyeth)
  • Other Anti-bacterial Drugs
  • Other Select Anti-bacterials Worldwide
  • Details of Other Select Anti-bacterial Drugs Worldwide
  • Zyvox (Pfizer)
  • Cubicin (Cubist Pharmaceuticals)
  • Targocid (Sanofi-Aventis/Astellas)
  • Vancomycin (Eli Lilly)
  • Carbapenems
  • Faropenem (Replidyne)
  • Primaxin (Merck & Co.)
  • Merrem/Meronem (AstraZeneca)

3. AN OVERVIEW OF BACTERIAL INFECTIONS

AND TREATMENT
  • Bacterial Infections
  • Types of Bacteria and Bacterial Infections
  • Overview of Select Bacterial Infections
  • Pneumonia
  • Intra-Abdominal Infections
  • Central Nervous System Infections
  • Bloodstream Infections
  • Bone Infections
  • Surgical Site Infections
  • Urinary Tract Infections
  • Urethritis
  • Hemorrhagic Cystitis
  • Acute Pyelonephritis
  • Anti-bacterial Drugs to Combat Against Bacteria
  • Launch Year of Different Anti-Bacterial Drug Classes
  • Anti-bacterial Categorization
  • Classification Based on Action Mechanism
  • Classification Based on Method of Suppressing Bacterial Growth
  • Bactericidal Drugs
  • Bacteriostatic Drugs
  • Classification Based on Spectra of Activity
  • Anti-Bacterial Drug Classes and their Uses
  • Cephalosporins
  • Treatment
  • Side Effects
  • Penicillins
  • History
  • Types of Penicillins
  • Side Effects
  • Fluoroquinolones
  • Treatment
  • Major Fluoroquinolones Worldwide, Along with Indications
  • Side Effects
  • Macrolides
  • Select Macrolides and its Derivatives by Development Stage (As of 2008)
  • Treatment
  • Side Effects
  • Other Antibacterials
  • Aminoglycosides
  • Treatment
  • Aminoglycosides and Indications
  • Side Effects
  • Tetracyclines
  • Treatment
  • Side Effects
  • Sulfonamides
  • Treatment
  • Effects of the Drug
  • Mupirocin
  • Carbepenems
  • Aztreonam
  • Glycopeptides
  • Vancomycin
  • Teicoplanin
  • Bacitracin
  • Lincosamines
  • Polymyxins
  • Chloramphenicol
  • Limitations of Antibacterial Therapy
  • Bacterial Resistance
  • Antibacterial-Resistant Bacteria by Type
  • Cross-resistance
  • Phage Therapy, a Promising Approach for Bacterial Infections
  • Treatment and Application of Phase Therapy
  • Phages for Antibiotic-Resistant Bacteria
  • Companies Involved in Phage Therapy Research

4. PRODUCTS INTRODUCTIONS/APPROVALS/

CLINICAL TRIALS
  • Johnson & Johnson Receives Complete Response Letter for Ceftobiprole from US FDA
  • Negative Opinion on Ceftobiprole by European CHMP
  • Theravance and Astellas Obtains FDA Approval for VIBATIV(tm) for Treating Complicated Skin and Skin Structure Infections (cSSSI)
  • Daiichi Sankyo Company Introduces Cravit(r) Formulations
  • Forest Labs Announces Encouraging Phase III Results of Ceftaroline
  • Cubist Pharma Initiates First-In-Human Clinical Trial with CB-183,315
  • Basilea Pharmaceutica Announces New Research Results for BAL30072 in Multi- Resistant Gram- Negative Bacteria
  • Galderma Laboratories Launches Epiduo(tm) Gel for Acne Treatment
  • Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug
  • US FDA Asks Arpida to Secure Additional Data for Iclaprim
  • MiddleBrook Obtains FDA Approval for MOXATAG(tm)
  • MIT Scientists Develop a New Antibiotic, Rhodostreptomycin
  • Watson Pharma Introduces Biaxin XL' s Generic Version
  • Taisho Toyama Pharmaceutical Rolls Out Zosyn(r) to Treat Severe Bacterial Infections
  • GSK Launches ALTARGO(r) in the UK
  • Daiichi Obtains Approval for Gracevit(r)
  • New Research Backs LEVAQUIN Use in CAP Treatment in Concordance with Guidelines
  • FDA Instructs Targanta to Conduct Additional Oritavancin Trials
  • J&J' s Doribax Obtains FDA Approval for Urinary Tract and Intra-abdominal Infections
  • APL Receives FDA Approval for Cefpodoxime Proxetil
  • Toyama Launches New Garenoxacin Quinolone Antibiotic
  • Wockhardt to Introduce Cefprozil Tablets in the US
  • MSD India Launches Invanza in India
  • Macrolide Antibiotic Developed in the US
  • GSK Obtains EC Approval for Altargo(r) in Treating Skin Infections

5. RECENT INDUSTRY ACTIVITY

  • Pfizer Indicts Teva for Zyvox Patent Infringement
  • Beactica and Cubist Sign Agreement to Develop Advanced Anti-Bacterials
  • Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin
  • Forest Laboratories Collaborates with AstraZeneca to Co-Develop Ceftaroline
  • TB Alliance Enters into Multiple Deals for TB Drug Discovery
  • Kemin Industries Acquires Amalyte Pharmaceuticals
  • Forma Therapeutics Sign Deal with Cubist to Make Antibacterial Drugs
  • Lee' s Pharmaceutical Holdings Acquires Rights to Oral Antibacterial Drug
  • Anacor Pharmaceuticals Collaborates with TB Alliance
  • Jiangchuan Pharmaceutical Forges Joint Venture with Sichuan Mingxin
  • Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery
  • Abbott Acquires Ibis Biosciences
  • Elder and Strides on Expansion Mode
  • Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma
  • Akorn Signs Agreement with Eli Lilly and Company
  • NovaBay Inks Agreement with Medical University of Innsbruck
  • Tibotec Collaborates with Global Alliance for TB Drug Development
  • Sandoz Introduces Generic Maxipime(r)
  • Merck and Ranbaxy to Launch Anti-Bacterial and Anti-Fungal Drugs
  • Wyeth Receives an Approvable Letter from US FDA for TYGACIL(r)
  • Mylan Receives FDA Approval for Linezolid 600 mg Tablets
  • Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden
  • MiddleBrook Obtains NDA Approval for MOXATAG(tm)
  • ULL Establishes New Antibiotics Unit in Himachal Pradesh
  • Biocat to Expand Presence in the Indian Market
  • Novartis to Acquire Protez
  • Orchid Signs Licensing Agreement with Merck
  • Forest and Novexel Sign Licensing Agreement
  • Sanofi-aventis Collaborates with Novozymes
  • AstraZeneca Acquires Arrow Therapeutics
  • Cubist Submits INDs for CB-182,804 and CB-183,315
  • GlaxoSmithKline Enters into Strategic Alliance with Mpex Pharmaceuticals to Develop Novel Drugs to treat Bacterial Diseases
  • Advanced Life Sciences and Wyeth Pharmaceuticals Sign Marketing Deal for Commercialization of Cethromycin in Asia Pacific
  • GlaxoSmithKline Receives FDA Approval for Altabax
  • GSK and Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals
  • Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN(r)
  • Cubist Obtains Approval to Market CUBICIN for Added Indications in EU
  • Cubist Gains Approval for CUBICIN in Taiwan and South Korea
  • Cethromycin Achieves FDA' s Orphan Drug Designation
  • GSK Receives Approval for ALTARGO(r) in Europe
  • sanofi-aventis Updates Prescription Information for Ketek in the US

6. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • AstraZeneca PLC (UK)
  • Bayer HealthCare AG (Germany)
  • Bristol-Myers Squibb Co. (USA)
  • Cubist Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo Company, Ltd. (Japan)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson (USA)
  • Pfizer, Inc. (US)
  • Wyeth Pharmaceuticals, Inc. (US)

7. GLOBAL MARKET PERSPECTIVE

  • Table 4: World Recent Past, Current & Future Analysis for Antibacterial Drugs by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 5: World 10-Year Perspective for Antibacterial Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 6: World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 7: World 10-Year Perspective for Cephalosporins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 8: World Recent Past, Current & Future Analysis for Penicillins by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 9: World 10-Year Perspective for Penicillins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 10: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 11: World 10-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 12: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 13: World 10-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
  • Table 14: World Recent Past, Current & Future Analysis for Other Anti-bacterial Drugs by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 15: World 10-Year Perspective for Other Anti-bacterial Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • Products Approvals/Launches/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 16: US Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 17: US 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 18: European Recent Past, Current & Future Analysis for Antibacterial Drugs by Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 19: European 10-Year Perspective for Antibacterial Drugs by Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)
    • Table 20: European Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class- Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 21: European 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2a. FRANCE

  • A. Market Analysis
    • Antibiotics Use Takes A Dip, As Regulatory Authorities' Efforts Pays Off
  • B. Market Analytics
    • Table 22: French Recent Past, Current & Future Analysis for Antibacterial Drugs- Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2b. GERMANY

  • A. Market Analysis
    • Key Player
    • Bayer HealthCare AG
  • B. Market Analytics
    • Table 23: German Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2c. ITALY

  • Market Analysis
  • Table 24: Italian Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2d. THE UNITED KINGDOM

  • A. Market Analysis
    • Infectious Diseases - A Quick Primer
    • Research and Development of New Anti-Infectives
    • Products Introduction
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 25: UK Recent Past, Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2e. SPAIN

  • Market Analysis
  • Table 26: Spanish Recent Past, Current & Future Analysis for Antibacterial Drugs-Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2f. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Development
    • Key Player
    • F. Hoffmann-La Roche, Ltd. (Switzerland)
  • B. Market Analytics
    • Table 27: Rest of Europe Recent Past Current & Future Analysis for Antibacterial Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC

  • A. Market Analysis
    • Focus on Select Regional Markets
    • China
    • Carbapenem Antibiotics Hold Great Potential
    • India
    • Injectable Antibiotics Demonstrate Robust Growth
    • New Initiative to Develop Novel Antibiotic Molecules
    • Products Introductions/Developments
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 29: Asia-Pacific 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 30: Rest of World Recent Past, Current & Future Analysis for Antibacterial Drugs by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
    • Table 31: Rest of World 10-Year Perspective for Antibacterial Drugs by Drug Class - Percentage Breakdown of Dollar Sales for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Other Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top